The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Share News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.675
Bid: 0.65
Ask: 0.70
Change: 0.00 (0.00%)
Spread: 0.05 (7.692%)
Open: 0.675
High: 0.675
Low: 0.675
Prev. Close: 0.675
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: N4's Nuvec success; Watkin Jones tumbles

Tue, 04th Oct 2022 11:19

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

----------

AIM - WINNERS

----------

N4 Pharma PLC, up 10% at 2.20 pence, 12-month range 1.50p-8.69p. The company announces two successful in vitro tests of Nuvec when loaded with two small interfering siRNA probes. siRNA can prevent cells from communicating, and could potentially prevent cancer cells from replicating. After announcing in September that it would focus on developing multiple loaded siRNA on Nuvec, N4 says it has now completed in vitro testing, which shows both probes were able to "significantly silence" their respective targets.

----------

AIM - LOSERS

----------

Watkin Jones PLC, down 33% at 101.69p, 12-month range 97.30p-282.08p. It expects to miss full-year profit expectations. The London-based student accommodation developer and manager says that in the first half to September 30, cost inflation was mitigated by increasing asset values, however in the second half it sees some pricing and margin "softness" on sales. It adds that two forward sales which were expected to close in September have been impacted by recent market volatility, and are now expected to go through in financial year 2023.

----------

Allergy Therapeutics PLC, down 11% at 17.00p, 12-month range 15.25p-40.50p. It pauses production at the Freeman facility, part of its Worthing, UK manufacturing site. Allergy Therapeutics says that the facility has been closed to accelerate ongoing site improvements.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
9 Jul 2018 08:40

N4 Pharma Shares Fall As Sildenafil Trial Falls Short Of Expectations

LONDON (Alliance News) - Shares in N4 Pharma PLC plunged early Monday as the company said that its sildenafil reformulation clinical trial has not met its key target endpoints.Shares in the

Read more
18 Jun 2018 11:54

N4 Pharma Says Team Making Progress In Nuvec Manufacturing Process

LONDON (Alliance News) - Drug reformulator N4 Pharma PLC said Monday work to develop a manufacturing process for Nuvec has begun "well" with the team making progress.Nuvec is a to

Read more
9 May 2018 14:13

N4 Pharma Files Patent For Drug To Treat Premature Ejaculation

LONDON (Alliance News) - Pharmaceutical company N4 Pharma PLC announced on Wednesday it has filed a patent application for a treatment for premature ejaculation.N4 Pharm's drug is an of

Read more
25 Apr 2018 11:54

N4 Pharma Outlook Optimistic But Loss Widens After Reverse Takeover

LONDON (Alliance News) - N4 Pharma PLC on Wednesday said it remains optimistic for future as progresses its drug and vaccine development, but the company's loss widened in 2017 following its a

Read more
18 Apr 2018 12:15

N4 Pharma Starts Clinical Trial Of Reformulated Sildenafil

LONDON (Alliance News) - N4 Pharma PLC said Wednesday that it has commenced proof of concept clinical trial for erectile dysfunction treatment drug sildenafil, following the completion of the of a

Read more
9 Mar 2018 10:43

N4 Pharma Raises Nets GBP159,700 From Warrant Exercise (ALLISS)

LONDON (Alliance News) - N4 Pharma PLC said Friday it issued 1.9 million shares due to exercise of warrants, raising GBP159,700 for the pharmaceutical warrants

Read more
8 Mar 2018 13:34

N4 Pharma Unveils Two-Pronged Strategy For Nuvec Development

LONDON (Alliance News) - N4 Pharma PLC announced Thursday a two-fold development strategy for its Nuvec technology, as well as a new head of development for Nuvec.Nuvec

Read more
7 Mar 2018 12:41

N4 Pharma Raises Further GBP30,451 After Warrant Exercise (ALLISS)

LONDON (Alliance News) - N4 Pharma PLC said Wednesday it issued 358,245 shares due to exercise of warrants, raising GBP30,451 for the pharmaceutical warrants at

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.